Top 11 CRISPR Stocks to Invest In

4. Qiagen N.V. (NYSE:QGEN)

Number of Hedge Fund Holders: 26

Qiagen NV (NYSE:QGEN) is a leading provider of sample and assay technologies for molecular diagnostics, applied testing, academic, and pharmaceutical research. Renowned for its robust portfolio in healthcare, the company focuses on biotechnology, genomics research, and point-of-care diagnostics. Qiagen NV (NYSE:QGEN) recently enhanced its product offerings with the introduction of the QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions, which streamline gene-editing workflows by integrating liquid-based sample preparation with PCR detection and Sanger sequencing.

On December 9, Jefferies initiated coverage of Qiagen NV (NYSE:QGEN) with a Buy rating and a price target of $54. The firm highlighted Qiagen’s competitive edge through its comprehensive product lineup spanning sample technologies, molecular diagnostics (qPCR and dPCR), and genomic consumables. Qiagen’s strong presence in high-margin sample-prep instrumentation and blood-based tuberculosis testing provides a solid foundation for its growth. Jefferies also cited the company’s Five Pillar growth strategy, which aims to deliver double-digit earnings growth through 2028, driven by mid-to-high single-digit revenue growth.

Qiagen NV (NYSE:QGEN) exceeded Q3 expectations, reporting $502 million in sales, reflecting a 6% increase at constant exchange rates. Adjusted diluted EPS reached $0.57, surpassing the $0.55 estimate. The company raised its 2024 adjusted EPS target to $2.19, up from $2.16, and projected a minimum Q4 adjusted EPS of $0.60. Key growth drivers included the Diagnostic Solutions product group and consumables, with the QIAstat product line achieving an impressive 40% growth. Moreover, the company reaffirmed its 2024 sales outlook, forecasting at least $1.985 billion.